Thank you to @mlblack1_b@cityofhope for the write-up of her talk today and the overview of what we are trying to do at @NIH to move precision oncology forward for patients with AML in remission but at continued risk of relapse.
A new guideline from @ASTCT Committee on Practice Guidelines reviews hematopoietic cell transplantation in the management of myelodysplastic syndrome: https://t.co/bRkXs04ki8 #openaccess#MMsm @ELShematology
Nice review on myelofibrosis current&upcoming Rx. Disheartens me however➡️BMT wrapped in 2 paragraphs when it’s the only modality that moves the needle for MF patients & no drugs “in the pipeline” alter natural history #mpnsm#bmtsm @BloodJournal https://t.co/3XR7LXQqiH
It’s a beautiful fall day at the capitol with the @ASH_hematology crew! Ready to #Fight4Hematology and #ConquerSCD! We’re here asking for:
⭐️@NIH funding to $49 billion
⭐️#SCD@CDCgov data collection to $10 million
⭐️#sicklecell Medicaid Demonstration Bill (S.3389 & H.R.6216)
We are excited to share the results of our cost effectiveness analysis of second line axi-cel in DLBCL published in Blood. Despite the high cost of CAR T, we demonstrate that second line axi-cel is cost effective if 5-year EFS is at least 26%. https://t.co/BPeYm59z99
LIFE HISTORY of Investigator-initiated (sponsored) trial (IIT / IST) A🧵
Day 1. An idea. It came to you. Or came to your mentor. You saw something somewhere. Maybe it was @ASH or @ASCO. You connected the dots.
Month 1. You discuss it with your group. 1/19
Published now @BloodCancerJNL 📢 Triplets (LIC+VEN+FLT3i) outperforms doublets (LIC+FLT3i) in frontline older/unfit FLT3m #AML. CR/CRi, MFC negativity, and the 2-year OS rates ➡ 93% vs. 70%, 83% vs. 38%, and 70% vs. 22%
👇
https://t.co/9TMf8NRG0t
@MusaYilmazMD @DaverLeukemia
Can you spot AML w/ inv(3)(q21q26) when you see it? 🕵🏻♀️It’s among the most aggressive forms of AML. Diagnostic clues: marked anemia+normal plt count, multilineage dysplasia +/- megakaryocytic hyperplasia and strikingly small megakaryocytes (red arrows) #hemepath 1/ 🧵 #leusm
📢Out now in @AjHematology via @MDAndersonNews#Leukemia👉 Extended follow up (median 20 mo.) with expanded enrollment (N=45) of FLAG-IDA-VEN in ND-AML | ORR: 98% | CRc: 89% | ⏫ MRD-neg CRc: 93%| 24-month OS 85% in ELN adv. risk w/o TP53 mut.
Link👇
https://t.co/mWG5Pbyufm
Out now in @TheLancetHaem via @MDAndersonNews Leukemia | Outcomes of venetoclax combined with IC in #AML | VEN+IC👉 improved MRD-negative CR rates, transition to alloHSCT, and EFS compared to IC alone.
https://t.co/4NpbbuyGrC
#leusm
Exciting to see this prepublished online in @BloodJournal https://t.co/WGHujqpYo2
We found that the CD19 #CARTcell product type independently impacts outcomes in relapsed or refractory aggressive B-NHL.
First CAR-T collaboration between @fredhutch and @OHSUNews 😄
Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May @ASGCT in Washington DC @Cancer_Cell https://t.co/Bg744JbD4t